Clinical Trial Update: Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating subcutaneous semaglutide at 1, 3, and 10 mg/mL and its absolute bioavailability; the trial has completed in diabetes me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED